Pharmacokinetics of Caspofungin
NCT03399032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 33
Last updated 2023-11-24
Summary
The objective of this study is to describe the pharmacokinetics of standard doses of caspofungin in critically ill patients.
Conditions
- Septic Shock
- Fungal Infection
- Critical Illness
Interventions
- DRUG
-
Caspofungin
Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days.
Sponsors & Collaborators
-
Medical University of Lublin
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-05
- Primary Completion
- 2018-08-06
- Completion
- 2018-09-03
Countries
- Poland
Study Locations
More Related Trials
-
Population Pharmacokinetics of Anti-infectives in Hospitalized Patients
NCT02998411 ·Status: RECRUITING
-
Candida Host Defense Response After Septic Shock in the Critically Ill
NCT03136081 ·Status: COMPLETED
-
Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients
NCT02993575 ·Status: COMPLETED
-
Anidulafungin Pharmacokinetics in Intensive Care Unit Patients
NCT01438216 ·Status: UNKNOWN
-
Detection of Clindamycin Resistance Antibiotic Genes Among Staphylococcus Isolates by Using Real Time PCR
NCT04933019 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients
NCT02408185 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF
NCT04358991 ·Status: COMPLETED
-
Pharmacokinetics of Ceftriaxone Free Fraction
NCT05061875 ·Status: UNKNOWN
-
Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
NCT03309657 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
NCT01669980 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacodynamic Parameters of Two Different Doses of Cefepime
NCT00177736 ·Status: COMPLETED
-
Tissue Penetration of Antibiotics in Obesity
NCT00752908 ·Status: COMPLETED
-
Subcutaneous Daptomycin in Healthy Volunteers (DAPTOSC)
NCT04434300 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Antibiotics in Critically Ill Patients Receiving CVVHF
NCT04800952 ·Status: UNKNOWN ·Phase: NA
-
Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
NCT02387372 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
NCT04470973 ·Status: UNKNOWN
-
Pharmacological Study of High Doses of Ceftriaxone in Meningitidis
NCT01745679 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis
NCT03681431 ·Status: COMPLETED ·Phase: PHASE2
-
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
NCT04319328 ·Status: COMPLETED
-
Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients
NCT04257812 ·Status: UNKNOWN
-
A Study the Population Pharmacokinetics of Children of Infectious Disease in Central Nervous System
NCT03960905 ·Status: UNKNOWN
-
Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy
NCT00214331 ·Status: COMPLETED
-
Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis
NCT02556190 ·Status: COMPLETED
-
Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling
NCT06956053 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Incidence and Risk Factors for Developing Infections in Patients Colonized by CP-KPC
NCT05492539 ·Status: UNKNOWN